vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and MAXIMUS, INC. (MMS). Click either name above to swap in a different company.

MAXIMUS, INC. is the larger business by last-quarter revenue ($1.3B vs $749.2M, roughly 1.7× CLOVER HEALTH INVESTMENTS, CORP.). MAXIMUS, INC. runs the higher net margin — 30.2% vs 3.6%, a 26.5% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -2.8%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -0.3%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Maximus Inc. is an American government services company, with operations in countries including the United States, Canada, and the United Kingdom. Maximus provides administration and other services for Medicaid, Medicare, health care reform, welfare-to-work, and student loan servicing, among other government programs. The company is based in Tysons, Virginia, has 39,600 employees and a reported annual revenue of $5.3 billion in fiscal year 2024.

CLOV vs MMS — Head-to-Head

Bigger by revenue
MMS
MMS
1.7× larger
MMS
$1.3B
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+64.8% gap
CLOV
62.0%
-2.8%
MMS
Higher net margin
MMS
MMS
26.5% more per $
MMS
30.2%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-0.3%
MMS

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
CLOV
CLOV
MMS
MMS
Revenue
$749.2M
$1.3B
Net Profit
$27.3M
$394.0M
Gross Margin
26.2%
Operating Margin
3.6%
11.4%
Net Margin
3.6%
30.2%
Revenue YoY
62.0%
-2.8%
Net Profit YoY
-4.1%
EPS (diluted)
$0.05
$7.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
MMS
MMS
Q1 26
$749.2M
$1.3B
Q4 25
$487.7M
$1.3B
Q3 25
$496.6M
$1.3B
Q2 25
$477.6M
$1.3B
Q1 25
$462.3M
$1.4B
Q4 24
$337.0M
$1.4B
Q3 24
$331.0M
$1.3B
Q2 24
$356.3M
$1.3B
Net Profit
CLOV
CLOV
MMS
MMS
Q1 26
$27.3M
$394.0M
Q4 25
$-49.3M
$93.9M
Q3 25
$-24.4M
$75.3M
Q2 25
$-10.6M
$106.0M
Q1 25
$-1.3M
$96.6M
Q4 24
$-22.1M
$41.2M
Q3 24
$-9.2M
$72.5M
Q2 24
$7.4M
$89.8M
Gross Margin
CLOV
CLOV
MMS
MMS
Q1 26
26.2%
Q4 25
23.7%
Q3 25
25.3%
Q2 25
26.7%
Q1 25
24.9%
Q4 24
21.5%
Q3 24
24.5%
22.9%
Q2 24
30.3%
25.3%
Operating Margin
CLOV
CLOV
MMS
MMS
Q1 26
3.6%
11.4%
Q4 25
-10.1%
10.9%
Q3 25
-4.9%
9.3%
Q2 25
-2.2%
12.3%
Q1 25
-0.3%
11.2%
Q4 24
-6.4%
6.2%
Q3 24
-2.7%
8.5%
Q2 24
2.0%
10.8%
Net Margin
CLOV
CLOV
MMS
MMS
Q1 26
3.6%
30.2%
Q4 25
-10.1%
7.0%
Q3 25
-4.9%
5.7%
Q2 25
-2.2%
7.9%
Q1 25
-0.3%
7.1%
Q4 24
-6.6%
2.9%
Q3 24
-2.8%
5.5%
Q2 24
2.1%
6.8%
EPS (diluted)
CLOV
CLOV
MMS
MMS
Q1 26
$0.05
$7.27
Q4 25
$1.70
Q3 25
$1.27
Q2 25
$1.86
Q1 25
$1.69
Q4 24
$0.69
Q3 24
$1.18
Q2 24
$1.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
MMS
MMS
Cash + ST InvestmentsLiquidity on hand
$177.6M
$157.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$339.4M
$1.7B
Total Assets
$697.7M
$4.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
MMS
MMS
Q1 26
$177.6M
$157.5M
Q4 25
$78.3M
$137.6M
Q3 25
$222.4M
Q2 25
$59.8M
Q1 25
$108.1M
Q4 24
$194.5M
$72.7M
Q3 24
$288.0M
$183.1M
Q2 24
$254.8M
$102.8M
Stockholders' Equity
CLOV
CLOV
MMS
MMS
Q1 26
$339.4M
$1.7B
Q4 25
$308.7M
$1.7B
Q3 25
$340.9M
$1.7B
Q2 25
$344.2M
$1.8B
Q1 25
$336.1M
$1.7B
Q4 24
$341.1M
$1.6B
Q3 24
$342.2M
$1.8B
Q2 24
$324.9M
$1.8B
Total Assets
CLOV
CLOV
MMS
MMS
Q1 26
$697.7M
$4.2B
Q4 25
$541.0M
$4.2B
Q3 25
$559.7M
$4.1B
Q2 25
$575.0M
$4.5B
Q1 25
$583.7M
$4.2B
Q4 24
$580.7M
$4.1B
Q3 24
$653.0M
$4.1B
Q2 24
$674.2M
$4.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
MMS
MMS
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$450.0M
FCF MarginFCF / Revenue
34.5%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$643.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
MMS
MMS
Q1 26
Q4 25
$-66.9M
$-244.4M
Q3 25
$12.1M
$649.4M
Q2 25
$5.4M
$-182.7M
Q1 25
$-16.3M
$42.7M
Q4 24
$34.8M
$-80.0M
Q3 24
$50.0M
$163.8M
Q2 24
$44.8M
$199.3M
Free Cash Flow
CLOV
CLOV
MMS
MMS
Q1 26
$450.0M
Q4 25
$-69.0M
$-250.7M
Q3 25
$11.4M
$641.8M
Q2 25
$4.8M
$-198.2M
Q1 25
$-16.5M
$25.5M
Q4 24
$33.3M
$-103.0M
Q3 24
$49.6M
$131.9M
Q2 24
$44.4M
$164.6M
FCF Margin
CLOV
CLOV
MMS
MMS
Q1 26
34.5%
Q4 25
-14.1%
-18.6%
Q3 25
2.3%
48.7%
Q2 25
1.0%
-14.7%
Q1 25
-3.6%
1.9%
Q4 24
9.9%
-7.3%
Q3 24
15.0%
10.0%
Q2 24
12.5%
12.5%
Capex Intensity
CLOV
CLOV
MMS
MMS
Q1 26
Q4 25
0.4%
0.5%
Q3 25
0.1%
0.6%
Q2 25
0.1%
1.1%
Q1 25
0.0%
1.3%
Q4 24
0.5%
1.6%
Q3 24
0.1%
2.4%
Q2 24
0.1%
2.6%
Cash Conversion
CLOV
CLOV
MMS
MMS
Q1 26
Q4 25
-2.60×
Q3 25
8.63×
Q2 25
-1.72×
Q1 25
0.44×
Q4 24
-1.94×
Q3 24
2.26×
Q2 24
6.04×
2.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons